Scienture Holdings, Inc. SCNX
2.76 USD -0.23 (-7.69%)
Regular-session close
2.78 +0.02 +0.72%
After hours · Nov 17, 4:00 PM ET
2.73 Day range 3.00
2.64 52-week range 18.75
- YTD
- -78.35%
- 1 year
- -81.20%
News
globenewswire.com SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™ Q3 2026 Revenue Increased Approximately 113% Year-Over-Year to $1.25 Million Arbli ™ generated approximately $330,000 and $730,000 of Net Product Revenue for Q3 2026 and the first nine months of 2026…benzinga.com Scienture Holdings Q3 EPS $(3.76) Misses $(1.57) Estimate, Sales $1.255M Beat $1.220M Estimate Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(3.76) per share which missed the analyst consensus estimate of $(1.57) by 139.49 percent. This is a 21.01 percent increase over losses…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 16.1% to $0.92 during Thursday's after-market session. The company's market cap stands at $2.2 million. CareDx (NASDAQ:CDNA) stock rose 15.0% to…
seekingalpha.com Scienture Holdings, Inc. (SCNX) Shareholder/Analyst Call Prepared Remarks Transcript Scienture Holdings, Inc. (SCNX) Shareholder/Analyst Call Prepared Remarks Transcriptbenzinga.com Maxim Group Maintains Buy on Scienture Holdings, Adjusts Price Target To $6 (reverse stock split 1:25) Maxim Group analyst Naz Rahman maintains Scienture Holdings (NASDAQ:SCNX) with a Buy, adjusts target to $6 from $37.5 (reverse stock split 1:25).
benzinga.com Scienture Holdings Reports Preliminary Q3 Revenue Growth To $1.22M; Co Targeting Profitability In 2027 Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli™ Growth and the Commercial Launch of REZENOPY™Two FDA-Approved…
globenewswire.com SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027 Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli ™ Growth and the Commercial Launch of REZENOPY ™
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX)…
globenewswire.com SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth Continued Arbli ™ sales growth, combined with REZENOPY ™ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth
globenewswire.com SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals Major Institutional Formulary Win Expands Arbli ™ 's Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially
globenewswire.com Scienture Holdings, Inc. Announces Reverse Stock Split COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on…
globenewswire.com SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner Agreement provides dedicated commercial channel for REZENOPY ™ across approximately 2,000 OTP (Opioid Treatment Program) Clinics and other Addiction Treatment Center Networks in the United States
globenewswire.com SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 Management to Highlight Growing Commercial Momentum of Arbli ™ and the Commercial Launch of REZENOPY ™
globenewswire.com SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance Q2 2026 Gross Margin Was Approximately 97.7%, Reflecting the Company's Growing Commercial Revenue Base Q2 2026 Operating Loss Improved Approximately 48% Year-over-Year to Approximately $2.7 Million…
globenewswire.com SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray Commercial launch supported by a dedicated national sales force, payer and institutional access, and multi-channel marketing campaign supporting adoption of REZENOPY ™
globenewswire.com SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers Commercial availability expected in August as the Company advances the rollout of the highest-dose FDA-approved naloxone hydrochloride nasal spray U. S. naloxone market totals ~$144 million in annual…
globenewswire.com SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide Broader pharmacy access, channel expansion, and payer coverage position Arbli ™ for increased prescription volume and revenue growth
globenewswire.com SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market
accessnewswire.com SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC COMMACK, NY / ACCESS Newswire / June 4, 2026 / SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced…
globenewswire.com SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041 U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for…
globenewswire.com SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) ("Scienture"), a holding company for existing and planned pharmaceutical operating companies focused on providing…
globenewswire.com Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline Proceeds support commercialization of Arbli ™ , the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY ™ , life-saving opioid overdose emergency treatment
globenewswire.com SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041 U. S. losartan market totals approximately $241M annually with around 72M prescriptions, creating a significant opportunity for ARBLI as the first FDA-approved ready-to-use oral suspension COMMACK,…
